Treatment Of Oropharyngeal Candidiasis By Oravig (Miconazole) Buccal Tablets

Treatment Of Oropharyngeal Candidiasis By Oravig (Miconazole) Buccal Tablets.

Strativa Pharmaceuticals today announced that the US Food and Drug Administration (FDA) has approved Oravig (miconazole) buccal tablets for the curing of oropharyngeal candidiasis (OPC), more commonly known as thrush, in adults and children stage 16 and older italy. Oravig is the head and only local, said medicament formulation of miconazole - an antifungal medication - approved for this use in the US.

Oravig, which adheres to the gum, utilizes innovative buccal pastille technology enabling once-daily dosing that delivers miconazole precisely at the local site of infection throughout the day with minimal systemic absorption hoodia pure pharmacy. Oravig is easy-to-use and provides patients with a flavorless, odorless and within treatment option that does not interfere with routine activities such as eating and drinking.

Oravig will be offered in a 50 mg dosage strength and is expected to be elbow in retail pharmacies in the third quarter of 2010. "The FDA approval of Oravig underscores Strativa's commitment to improving patients' overall care experience by bringing to market new products that fulfill valetudinarian needs," said John A MacPhee, President, Strativa Pharmaceuticals. "Oravig offers patients trial from thrush a proven effective treatment in a discreet and helpful once-daily formulation".

The FDA approval was based on two pivotal Phase III clinical trials. The initial study demonstrated that Oravig completely resolved signs and symptoms of OPC at rates alike to Mycelex Troche (clotrimazole) administered five times per daylight in HIV-positive patients. This randomized, double-blind, double-dummy trial was conducted in 577 HIV-positive patients in 28 sites in the United States, Canada, and South Africa. A assistant randomized, open-label, multicenter comparative hard times conducted in 282 patients who underwent radiotherapy for conk and neck cancer showed that Oravig is safe and effective in this patient population who often has reduced salivary flow.

OPC is an vocalized fungal infection most common in individuals with weakened immune systems - distinctively those with HIV/AIDS and those undergoing certain cancer treatments. OPC is a disruptive fit that results in lesions and inflammation in the mouth, and includes symptoms such as soreness, pain, burning and/or altered taste.

Oravig is approved in 26 countries and is currently being marketed in several EU territories including France, Germany and the UK under the merchandising regard Loramyc. Under an exclusive licensing compact with BioAlliance Pharma, Strativa received the exclusive US commercialization rights to Oravig (miconazole) buccal tablets. Under the terms of the agreement, the FDA okay triggered a $20 million milestone pay from Strativa to BioAlliance, for total milestone payments to date in the amount of $35 million. In ell to royalties on sales, BioAlliance may receive milestone payments on tomorrow sales.

Indication and Important Safety Information for Oravig. Oravig (miconazole) is indicated for the local healing of oropharyngeal candidiasis (OPC) in adults. Oravig (miconazole) is a buccal tablet designed to adhere to the gum. Patients should be advised not to crush, chew, or fall for the tablet.

During clinical trials, the most collective adverse events (greater than or equal to 2%) reported with Oravig were diarrhea (6,0%), nausea (4,6%), worry (5,0%), dysgeusia (2,9%), upper abdominal pain (2,5%), and vomiting (2,5%). Oravig is contraindicated in patients with a known hypersensitivity to miconazole, exploit protein concentrate, or any other component of the product.

Allergic reactions, including anaphylactic reactions and hypersensitivity, have been reported with the delivery of miconazole. Discontinue Oravig at once at the first sign of hypersensitivity. There is no information regarding cross-hypersensitivity between miconazole and other azole agents check this out. Monitor patients with a portrayal of hypersensitivity to azoles.

tag : oravig miconazole patients strativa buccal hypersensitivity local bioalliance milestone

Post a comment

Private comment



Dr. Alejandra Falto

Новые записи
Новые комментарии
Новые трэкбэки
Архив по месяцам
Форма поиска
RSS ссылка
Формуляр приглашения в блог-друзья

Добавить автора в блог-друзья